Literature DB >> 32206440

Unrelated cord blood transplantation versus haploidentical transplantation in adult and pediatric patients with hematological malignancies-A meta-analysis and systematic review.

Duihong Li1,2, Xiaofan Li1,2,3, Lianming Liao3, Nainong Li1,2,3.   

Abstract

Several clinical trials have compared the safety and efficacy of umbilical cord blood transplantation (UCBT) with haploidentical transplantation (HIT) in patients with hematological malignancies. To obtain more reliable evidence, we performed a systematic review and meta-analysis. Seven studies were included and there was a combined total of 102 children and 1311 adults undergoing UCBT, along with 94 children and 915 adults undergoing HIT. Pooled comparisons of studies of UCBT and HIT in children found that the incidence of chronic graft-versus-host disease (GVHD) and disease-free survival (DFS) at 2 years (RR 0.34, 95% CI (0.03, 4.53), P=0.41; HR 0.51, 95% CI (0.23, 1.09), P=0.08) were not statistically different. For adults, although the incidence of grade II-IV acute GVHD differ (RR 1.17, 95% CI (1.02, 1.34), P=0.02), but it indicates a very small difference between the groups as the RR is barely above 1. On the other hand, although the incidence of grade III-IV acute GVHD did not differ (RR 1.51, 95% CI (0.78, 2.92), P=0.22), but there is a tendency of higher risk for the UCBT. And the incidence of chronic GVHD did not differ (RR 1.05, 95% CI (0.82, 1.34), P=0.71). There was no difference in relapse, non-relapse mortality (NRM) and DFS at 2 years (HR 0.92, 95% CI (0.74, 1.13), P=0.42; HR 0.87, 95% CI (0.49, 1.52) P=0.62 and HR 0.74 95% CI (0.39, 1.43), P=0.37). In conclusion, UCBT and HIT could be considered as equally effective option for adult patients without HLA-matched donors. AJBR
Copyright © 2020.

Entities:  

Keywords:  Umbilical cord blood transplantation; haploidentical transplantation; meta-analysis

Year:  2020        PMID: 32206440      PMCID: PMC7076284     

Source DB:  PubMed          Journal:  Am J Blood Res        ISSN: 2160-1992


  34 in total

1.  Comparison of outcomes after umbilical cord blood and unmanipulated haploidentical hematopoietic stem cell transplantation in children with high-risk acute lymphoblastic leukemia.

Authors:  Xiao-Dong Mo; Bao-Lin Tang; Xiao-Hui Zhang; Chang-Cheng Zheng; Lan-Ping Xu; Xiao-Yu Zhu; Yu Wang; Hui-Lan Liu; Chen-Hua Yan; Xian-Deng Chu; Huan Chen; Liang-Quan Geng; Kai-Yan Liu; Zi-Min Sun; Xiao-Jun Huang
Journal:  Int J Cancer       Date:  2016-07-15       Impact factor: 7.396

Review 2.  Cord blood transplantation: rewind to fast forward.

Authors:  A Dahlberg; F Milano
Journal:  Bone Marrow Transplant       Date:  2016-12-19       Impact factor: 5.483

3.  Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.

Authors:  Shannon R McCurdy; Jennifer A Kanakry; Margaret M Showel; Hua-Ling Tsai; Javier Bolaños-Meade; Gary L Rosner; Christopher G Kanakry; Karlo Perica; Heather J Symons; Robert A Brodsky; Douglas E Gladstone; Carol Ann Huff; Keith W Pratz; Gabrielle T Prince; Amy E Dezern; Ivana Gojo; William H Matsui; Ivan Borrello; Michael A McDevitt; Lode J Swinnen; B Douglas Smith; Mark J Levis; Richard F Ambinder; Leo Luznik; Richard J Jones; Ephraim J Fuchs; Yvette L Kasamon
Journal:  Blood       Date:  2015-03-26       Impact factor: 22.113

4.  Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors.

Authors:  Antonio Di Stasi; Denái R Milton; L M Poon; Amir Hamdi; Gabriela Rondon; Julianne Chen; Sai R Pingali; Marina Konopleva; Piyanuch Kongtim; Amin Alousi; Muzaffar H Qazilbash; Sairah Ahmed; Qaiser Bashir; Gheath Al-atrash; Betul Oran; Chitra M Hosing; Partow Kebriaei; Uday Popat; Elizabeth J Shpall; Dean A Lee; Marcos de Lima; Katayoun Rezvani; Issa F Khouri; Richard E Champlin; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2014-09-28       Impact factor: 5.742

5.  Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation.

Authors:  Dao-Pei Lu; Lujia Dong; Tong Wu; Xiao-Jun Huang; Mei-Jie Zhang; Wei Han; Huan Chen; Dai-Hong Liu; Zhi-Yong Gao; Yu-Hong Chen; Lan-Ping Xu; Yao-Chen Zhang; Han-Yun Ren; Dan Li; Kai-Yan Liu
Journal:  Blood       Date:  2005-12-27       Impact factor: 22.113

6.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.

Authors:  Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher
Journal:  PLoS Med       Date:  2009-07-21       Impact factor: 11.069

7.  Cord-Blood Transplantation in Patients with Minimal Residual Disease.

Authors:  Filippo Milano; Ted Gooley; Brent Wood; Ann Woolfrey; Mary E Flowers; Kristine Doney; Robert Witherspoon; Marco Mielcarek; Joachim H Deeg; Mohamed Sorror; Ann Dahlberg; Brenda M Sandmaier; Rachel Salit; Effie Petersdorf; Frederick R Appelbaum; Colleen Delaney
Journal:  N Engl J Med       Date:  2016-09-08       Impact factor: 91.245

8.  Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units.

Authors:  Michael R Verneris; Claudio G Brunstein; Juliet Barker; Margaret L MacMillan; Todd DeFor; David H McKenna; Michael J Burke; Bruce R Blazar; Jeffrey S Miller; Philip B McGlave; Daniel J Weisdorf; John E Wagner
Journal:  Blood       Date:  2009-08-25       Impact factor: 22.113

9.  Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis.

Authors:  Jennifer A Kanakry; Yvette L Kasamon; Javier Bolaños-Meade; Ivan M Borrello; Robert A Brodsky; Ephraim J Fuchs; Nilanjan Ghosh; Douglas E Gladstone; Christopher D Gocke; Carol Ann Huff; Christopher G Kanakry; Leo Luznik; William Matsui; Huzefa J Mogri; Lode J Swinnen; Heather J Symons; Richard J Jones; Richard F Ambinder
Journal:  Biol Blood Marrow Transplant       Date:  2013-07-18       Impact factor: 5.742

10.  Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide.

Authors:  Christopher G Kanakry; Sudipto Ganguly; Marianna Zahurak; Javier Bolaños-Meade; Christopher Thoburn; Brandy Perkins; Ephraim J Fuchs; Richard J Jones; Allan D Hess; Leo Luznik
Journal:  Sci Transl Med       Date:  2013-11-13       Impact factor: 17.956

View more
  1 in total

Review 1.  Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma.

Authors:  Darel Martínez Bedoya; Valérie Dutoit; Denis Migliorini
Journal:  Front Immunol       Date:  2021-03-03       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.